Aromatase-IN-8 

Aromatase-IN-8 is a selective Aromatase inhibitor against an IC₅₀ of 0.05 µM. Aromatase-IN-8 exhibits selective antiproliferative effects against estrogen receptor-positive breast cancer cell lines, while showing no toxicity toward non-tumoral cells. Aromatase-IN-8 suppresses estrogen active, increases testosterone levels, and downregulates estrogen receptor expression and phosphorylation. Aromatase-IN-8 can be used for triple negative breast cancer research^[1].

Aromatase-IN-8 (compound 17) (72 h) displays prominent anticancer effects in ER + breast cancer cell lines (T47D and MCF-7 cells) and triple-negative breast cancer cell line (MDA-231 cells) with IC₅₀ = 42.90, 79.43 and > 100 µM^[1].
Aromatase-IN-8 (6.25-100 µM, 24 and 72 h) reduces cell viability effects correlate with increasing dosage in MCF-7 cells and MDA-MB-231 cells^[1].
Aromatase-IN-8 (0-50 μM, 24 h) reduces ERα and ERβ protein levels in MCF-7 cells^[1].
Aromatase-IN-8 (6.25-50 μM, 8 h) reveals low 17β-estradiol and estrone small suppressive effects on estrogen synthesis leads to a more abundant accumulation of testosterone at concentrations above 12.5 µM in MCF-7 cells^[1].
Aromatase-IN-8 downregulates fatty acid degradation, upregulates pantothenate and CoA biosynthesis, valine and sphingosine accumulation and has the strong anticancer effects at higher doses in MCF-7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

346.88

C₁₇H₁₉ClN₄S

1244904-19-5

CC1=NN(C(Cl)=C1CN(CC2=CSC=C2)CC3=CN=CC=C3)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Maiuthed A, et al. An integrated computational, in vitro and metabolomics approach to the discovery of novel aromatase inhibitors with anti-breast cancer activities. Sci Rep. 2025 Nov 17;15(1):40230.  [Content Brief]